Details of the Drug

General Information of Drug (ID: DMA3DKO)

Drug Name
RIST4721
Synonyms
vimnerixin; AZD4721; RIST4721; AZD-4721; RIST-4721; X09ORN2BF0; 1418112-77-2; UNII-X09ORN2BF0; AZD-4721 [WHO-DD]; 1-Azetidinesulfonamide, N-(6-((1R,2S)-2,3-dihydroxy-1-methylpropoxy)-2-(((4-fluorophenyl)methyl)thio)-4-pyrimidinyl)-3-methyl-; vimnerixin [INN]; Azd 4721; CHEMBL5095217; SCHEMBL14579049; GTPL12100; AZD 4721 [WHO-DD]; AZD4721;RIST4721; AKOS040756752; compound 4 [WO2019055509A1]; MS-28748; HY-145640; CS-0377236; F83913; N-(6-{[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy}-2-{[(4-fluorophenyl)methyl]sulfanyl}pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide; N-[6-[(1R,2S)-2,3-Dihydroxy-1-methylpropoxy]-2-[[(4-fluorophenyl)methyl]thio]-4-pyrimidinyl]-3-methyl-1-azetidinesulfonamide; N-[6-[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy-2-[(4-fluorophenyl)methylsulfanyl]pyrimidin-4-yl]-3-methylazetidine-1-sulfonamide
Indication
Disease Entry ICD 11 Status REF
Hidradenitis suppurativa ED92.0 Phase 2 [1]
Palmoplantar pustulosis EA90.42 Phase 2 [2]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C19H25FN4O5S2
Canonical SMILES
CC1CN(C1)S(=O)(=O)NC2=CC(=NC(=N2)SCC3=CC=C(C=C3)F)OC(C)C(CO)O
InChI
InChI=1S/C19H25FN4O5S2/c1-12-8-24(9-12)31(27,28)23-17-7-18(29-13(2)16(26)10-25)22-19(21-17)30-11-14-3-5-15(20)6-4-14/h3-7,12-13,16,25-26H,8-11H2,1-2H3,(H,21,22,23)/t13-,16+/m1/s1
InChIKey
UCCNQCNIPRKLRP-CJNGLKHVSA-N
Cross-matching ID
PubChem CID
71209600
TTD ID
DW8Z1M
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C chemokine receptor type 2 (CXCR2) TT30C9G CXCR2_HUMAN Antagonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hidradenitis suppurativa
ICD Disease Classification ED92.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-X-C chemokine receptor type 2 (CXCR2) DTT CXCR2 8.82E-01 -0.23 -0.21
C-X-C chemokine receptor type 2 (CXCR2) DTT CXCR2 1.34E-01 0.21 0.19
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05348681) A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05194839) A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis. U.S.National Institutes of Health.
3 A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.